Update on Ablation for Barrett’s Esophagus

Esophagus (L Gerson, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Esophagus


Endoscopic ablation has dramatically changed the treatment algorithm for patients with Barrett’s esophagus. Studies clearly show the benefits of this approach for patients with high-grade dysplasia and intramucosal carcinoma. Recent studies also provide evidence in support of this approach for patients with low-grade dysplasia but not for patients with nondysplastic Barrett’s epithelium. Endoscopic ablation is safe and efficacious in most but not all patients and disease progression may occur during initial therapy as well as after successful completion in a small difficult to identify subset of patients. Furthermore, the past year has provided us with a better understanding of the durability of endoscopic ablation with highly variable rates of disease recurrence. Studies are underway to help determine predictors of response and recurrence.


Barrett’s esophagus Esophageal adenocarcinoma Dysplasia Radiofrequency ablation Endoscopic mucosal resection Cryotherapy 


Compliance with Ethics Guidelines

Conflict of Interest

Gary Falk has consulted for and received travel/accommodation expenses from Aptalis Pharma, Olympus and CDX.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology. 2011;140:1084–91.CrossRefPubMedGoogle Scholar
  2. 2.
    Ell C, May A, Pech O, Gossner L, Guenter E, Behrens A, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc. 2007;65:3–10.CrossRefPubMedGoogle Scholar
  3. 3.••
    Bennett C, Vakil N, Bergman J, Harrison R, Odze R, Vieth M, et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012;143:336–46. This international consensus provides evidence-based recommendations for the management of patients with high-grade dysplasia and intramucosal adenocarcinoma.CrossRefPubMedGoogle Scholar
  4. 4.
    Curvers WL, ten Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol. 2010;105:1523–30.CrossRefPubMedGoogle Scholar
  5. 5.
    Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med. 2009;360:2277–88.CrossRefPubMedGoogle Scholar
  6. 6.
    Phoa KY, van Vilsteren FG, Pouw RE, Weusten BL, Schoon EJ, Bisschops R, et al. Radiofrequency Ablation in Barrett's Esophagus With Confirmed Low-Grade Dysplasia: Interim Results of a European Multicenter Randomized Controlled Trial (SURF). Gastroenterology. 2013;144:S-187.Google Scholar
  7. 7.
    Hur C, Choi SE, Rubenstein JH, Kong CY, Nishioka NS, Provenzale DT, et al. The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology. 2012;143:567–75.CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med. 2011;365:1375–83.CrossRefPubMedGoogle Scholar
  9. 9.
    Solaymani-Dodaran M, Card TR, West J. Cause-specific mortality of people with Barrett's esophagus compared with the general population: a population-based cohort study. Gastroenterology. 2013;144:1375–83.CrossRefPubMedGoogle Scholar
  10. 10.
    Fleischer DE, Overholt BF, Sharma VK, Reymunde A, Kimmey MB, Chuttani R, et al. Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy. 2010;42:781–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Falk GW. Radiofrequency ablation of Barrett's esophagus: let's not get ahead of ourselves. Dig Dis Sci. 2010;55:1811–4.CrossRefPubMedGoogle Scholar
  12. 12.
    Manner H, Pech O, Heldmann Y, May A, Pohl J, Behrens A, et al. Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion. Clin Gastroenterol Hepatol. 2013;11:630–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Badreddine RJ, Prasad GA, Lewis JT, Lutzke LS, Borkenhagen LS, Dunagan KT, et al. Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma. Clin Gastroenterol Hepatol. 2010;8:248–53.CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    van Vilsteren FG, Phoa KN, Alvarez Herrero L, Pouw RE, Sondermeijer CM, van Lijnschoten I, et al. Circumferential balloon-based radiofrequency ablation of Barrett's esophagus with dysplasia can be simplified, yet efficacy maintained, by omitting the cleaning phase. Clin Gastroenterol Hepatol. 2013;11:491–8.CrossRefPubMedGoogle Scholar
  15. 15.
    van Vilsteren FG, Phoa KN, Alvarez Herrero L, Pouw RE, Sondermeijer CM, Visser M, et al. A simplified regimen for focal radiofrequency ablation of Barrett's mucosa: a randomized multicenter trial comparing two ablation regimens. Gastrointest Endosc. 2013;78:30–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Allen B, Kapoor N, Willert R, McEwan H, Fullarton G, Penman I. Endoscopic ablation of Barrett's neoplasia with a new focal radiofrequency device: initial experience with the Halo60. Endoscopy. 2012;44:707–10.CrossRefPubMedGoogle Scholar
  17. 17.••
    Orman ES, Li N, Shaheen NJ. Efficacy and Durability of Radiofrequency Ablation for Barrett's Esophagus: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1245–55. This systemic review and meta-analysis provides well-done summary estimates of the initial efficacy of radiofrequency ablation, long-term durability, and complication rates, albeit with considerable study heterogeneity.CrossRefPubMedGoogle Scholar
  18. 18.••
    Gupta M, Iyer PG, Lutzke L, Gorospe EC, Abrams JA, Falk GW, et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium. Gastroenterology. 2013;145:79–86. This large multicenter consortium cohort study shows that compete eradication of intestinal metaplasia and dysplasia takes considerably longer than initially thought, and that recurrence of intestinal metaplasia occurs at a high rate.CrossRefPubMedGoogle Scholar
  19. 19.••
    Haidry RJ, Dunn JM, Butt MA, Burnell MG, Gupta A, Green S, et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology. 2013;145:87–95. This large study of the British experience with radiofrequency ablation demonstrates a dysplasia clearance rate of 81 % at 1 year.CrossRefPubMedGoogle Scholar
  20. 20.
    Shaheen NJ, Kim HP, Bulsiewicz WJ, Lyday WD, Triadafilopoulos G, Wolfsen HC, et al. Prior fundoplication does not improve safety or efficacy outcomes of radiofrequency ablation: results from the U.S. RFA Registry. J Gastrointest Surg. 2013;17:21–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Hunt BM, Louie BE, Dunst CM, Lipham JC, Farivar AS, Sharata A, et al. Esophagectomy for failed endoscopic therapy in patients with high-grade dysplasia or intramucosal carcinoma. Dis Esophagus. 2013. doi: 10.1111/dote.12096.PubMedGoogle Scholar
  22. 22.
    Dulai PS, Pohl H, Levenick JM, Gordon SR, MacKenzie TA, Rothstein RI. Radiofrequency ablation for long- and ultralong-segment Barrett's esophagus: a comparative long-term follow-up study. Gastrointest Endosc. 2013;77:534–41.CrossRefPubMedGoogle Scholar
  23. 23.
    Shaheen NJ, Overholt BF, Sampliner RE, Wolfsen HC, Wang KK, Fleischer DE, et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology. 2011;141:460–8.CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    Orman ES, Kim HP, Bulsiewicz WJ, Cotton CC, Dellon ES, Spacek MB, et al. Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's esophagus with radiofrequency ablation. Am J Gastroenterol. 2013;108:187–95.CrossRefPubMedGoogle Scholar
  25. 25.••
    Phoa KN, Pouw RE, van Vilsteren FG, Sondermeijer CM, Ten Kate FJ, Visser M, et al. Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology. 2013;145:96–104. Follow-up of 54 patients in the Netherlands demonstrates a sustained remission rate of high-grade dysplasia and intramucosal cancer of 90 % at 5 years.CrossRefPubMedGoogle Scholar
  26. 26.
    Gosain S, Mercer K, Twaddell WS, Uradomo L, Greenwald BD. Liquid nitrogen spray cryotherapy in Barrett's esophagus with high-grade dysplasia: long-term results. Gastrointest Endosc. 2013;78:260–5.CrossRefPubMedGoogle Scholar
  27. 27.
    Spechler SJ, Sharma P, Traxler B, Levine D, Falk GW. Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. Am J Gastroenterol. 2006;101:1964–71.CrossRefPubMedGoogle Scholar
  28. 28.••
    Jovov B, Shaheen NJ, Orlando GS, Djukic Z, Orlando RC. Defective barrier function in neosquamous epithelium. Am J Gastroenterol. 2013;108:386–91. Ex-vivo studies of neosquamous Barretts epithelium demonstrates dilated intracellular space and increased permeability when compared to native squamous epithelium.CrossRefPubMedGoogle Scholar
  29. 29.
    Gupta N, Mathur SC, Dumot JA, Singh V, Gaddam S, Wani SB, et al. Adequacy of esophageal squamous mucosa specimens obtained during endoscopy: are standard biopsies sufficient for postablation surveillance in Barrett's esophagus? Gastrointest Endosc. 2012;75:11–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Zhou C, Tsai TH, Lee HC, Kirtane T, Figueiredo M, Tao YK, et al. Characterization of buried glands before and after radiofrequency ablation by using 3-dimensional optical coherence tomography (with videos). Gastrointest Endosc. 2012;76:32–40.CrossRefPubMedCentralPubMedGoogle Scholar
  31. 31.
    Krishnan K, Pandolfino JE, Kahrilas PJ, Keefer L, Boris L, Komanduri S. Increased risk for persistent intestinal metaplasia in patients with Barrett's esophagus and uncontrolled reflux exposure before radiofrequency ablation. Gastroenterology. 2012;143:576–81.CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    van Vilsteren FG, Alvarez Herrero L, Pouw RE, Schrijnders D, Sondermeijer CM, Bisschops R, et al. Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett's esophagus with early neoplasia: a prospective multicenter study. Endoscopy. 2013;45:516–25.CrossRefPubMedGoogle Scholar
  33. 33.
    Titi M, Overhiser A, Ulusarac O, Falk GW, Chak A, Wang K, et al. Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett's esophagus. Gastroenterology. 2012;143:564–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Konda VJ, Gonzalez Haba Ruiz M, Hart J, Waxman I. Development of subsquamous cancer after hybrid endoscopic therapy for intramucosal Barrett's cancer. Endoscopy. 2012;44 Suppl 2:E390-1.PubMedGoogle Scholar
  35. 35.
    Lee JK, Cameron RG, Binmoeller KF, Shah JN, Shergill A, Garcia-Kennedy R, et al. Recurrence of subsquamous dysplasia and carcinoma after successful endoscopic and radiofrequency ablation therapy for dysplastic Barrett's esophagus. Endoscopy. 2013;45:571–4.CrossRefPubMedGoogle Scholar
  36. 36.
    Allende D, Dumot J, Yerian L. Esophageal squamous cell carcinoma arising after endoscopic ablation therapy of Barrett's esophagus with high-grade dysplasia. Report of a case. Dis Esophagus. 2013;26:314–8.CrossRefPubMedGoogle Scholar
  37. 37.
    Gorospe EC, Gupta M, Prasad GA, Lewis JT, Wang KK. Double trouble: two cases of squamous carcinoma arising from Barrett's dysplasia after endoscopic mucosal resection. Am J Gastroenterol. 2012;107:1595–6.CrossRefPubMedGoogle Scholar
  38. 38.
    Dua KS, Merrill J, Komorowski R. Neosquamous epithelium after ablation of Barrett's epithelium: cause for concern? Gastrointest Endosc. 2012;76:1082–3.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Division of GastroenterologyUniversity of Pennsylvania Perelman School of MedicinePhiladelphiaUSA

Personalised recommendations